PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.44%
R&D growth less than half of CRVO's 5.59%. David Dodd would verify if efficiency advantage is sustainable.
34.62%
Similar G&A growth to CRVO's 37.03%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
-26.41%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
14.45%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
14.45%
Similar total costs growth to CRVO's 15.98%. Walter Schloss would investigate norms.
561.32%
Interest expense change of 561.32% while CRVO maintains costs. Bruce Berkowitz would investigate control.
-26.41%
Both companies reducing D&A. Martin Whitman would check industry patterns.
55.40%
EBITDA growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-14.45%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
231.19%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
43.33%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
561.32%
Tax expense change of 561.32% while CRVO maintains burden. Bruce Berkowitz would investigate strategy.
43.33%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
43.35%
EPS growth while CRVO declines. John Neff would investigate advantages.
43.35%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.